A comprehensive review of clinical data indicates that certain antidepressants offer superior long-term benefits for patients managing depression. The analysis, published in The Lancet Psychiatry, found that escitalopram, duloxetine, and agomelatine were more likely to sustain symptom improvement over time compared to fluoxetine.
Researchers also noted that patients taking escitalopram or duloxetine were less likely to discontinue their medication during the study period. These findings provide new context for a class of drugs that millions of people rely on for mental health stability.
Comparing Medication Effectiveness
The review analyzed data from 115 randomized controlled trials involving more than 30,000 participants. The researchers focused on long-term usage, defined as six months or more, to determine which medications helped people maintain their progress.

The main analysis combined results from 35 trials that directly compared one antidepressant against another. The data showed a clear advantage for escitalopram (Lexapro), duloxetine (Cymbalta), and agomelatine (Valdoxan) in terms of sustained response. Fluoxetine (Prozac) trailed these options in both symptom reduction and patient retention.
Escitalopram is currently the most prescribed antidepressant in Australia, ranking 13th among all prescriptions dispensed through the Pharmaceutical Benefits Scheme in 2024-2025. Duloxetine ranked 45th, while agomelatine is not available on the scheme.
Limitations and Real-World Usage
Despite the promising results, the study authors cautioned that the findings are not definitive. More than half of the trials included in the main analysis were assessed as having a high risk of bias. This suggests that some of the observed differences between medications might reflect limitations in the original studies rather than genuine clinical superiority.

Additionally, the definition of long-term in these trials was relatively short. Most studies followed participants for about six months after they started medication. Only six trials tracked patients for longer than six months. This gap is significant because many Australians take antidepressants for much longer periods.
Recent Australian data shows that nearly a quarter of people prescribed antidepressants were still receiving them two years later. Another study found the average duration of use is four years. Clinical guidelines recommend continuing treatment for at least six to 12 months after symptoms improve, but many patients stay on medication well beyond that window.
The review highlights that individual responses to medication vary widely. A drug that works well for one person may cause unacceptable side effects for another. Factors such as previous medical history, other health conditions, and personal preferences play a major role in determining the best treatment path.

Discontinuing antidepressants can also be challenging. Some patients experience withdrawal symptoms when trying to stop, which can make gradual reduction under medical supervision essential. The study notes that trial drop-out rates do not fully capture the complex trade-offs patients make between symptom relief and daily life impacts.
For those currently taking an antidepressant that is working effectively, the study results do not suggest a need to switch medications. Patients considering starting, changing, or stopping their treatment should discuss their options with a doctor to ensure the best outcome for their specific situation.
Source: ScienceDaily

